Literature DB >> 7685669

Cytochrome P450IID6 recognized by LKM1 antibody is not exposed on the surface of hepatocytes.

A M Yamamoto1, C Mura, C De Lemos-Chiarandini, R Krishnamoorthy, F Alvarez.   

Abstract

LKM1 autoantibody, directed against P450IID6, is accepted as a marker of a particular type of autoimmune hepatitis, but its role in the pathogenesis of the disease is controversial. Localization of P450IID6 on the cell surface of rat hepatocytes was previously reported, suggesting that membrane-bound P450IID6 could be the target of LKM1 antibodies, thus allowing immune lysis of hepatocytes. The objective of the present study was to determine, using various methods, the cell localization of P450IID6 in human and rat hepatocytes. Incubation of rat and human hepatocytes with LKM1-positive serum showed slight, if any, cell membrane staining using immunofluorescence, immunoperoxidase and immunoelectron microscopic studies. No staining of the plasma membrane of human hepatocytes was observed when incubations were carried out with immunoaffinity-purified antibody directed against peptide 254-271, the main epitope of P450IID6 recognized by all LKM1 sera tested. Chinese hamster ovary cells, transfected with the complete P450IID6 cDNA and incubated with the supernatant from a B cell lymphoblastoid cell line prepared with the lymphocytes of a LKM1-positive patient, did not show any staining of the cell surface by immunofluorescence. Incubation of rat microsomal fraction vesicles with LKM1-positive serum, followed by protein A-gold immunoelectron microscopy, displayed a staining of almost all vesicles, confirming that P450IID6 is present on the cytoplasmic side of the microsomal membrane, which makes it unable to be expressed on the cell surface even if it were transported from the endoplasmic reticulum (ER). Sulpho NHS Biotin labelling of rat hepatocyte cell membranes did not show the presence of a 50-kD molecule that could have reacted with LKM1 antibody. DNA sequencing of exon 1 of the CYP2D6 gene of a patient positive for LKM1 antibody did not show any difference from that of the normal published sequence of the gene. This does not favour an alteration of the NH2 terminal sequence of the P450IID6 molecule that could explain a translocation of the molecule to the luminal side of the ER, allowing its expression on the cell surface. These results indicate that, in all likelihood, P450IID6 molecule is not present on the cell surface of normal rat and human hepatocytes. Other mechanisms than antibody-mediated cell lysis directed against membrane P450IID6 antigenic determinants must be found to account for the destruction of hepatocytes observed in this disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685669      PMCID: PMC1554760          DOI: 10.1111/j.1365-2249.1993.tb03409.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  43 in total

1.  Characterization of rat hepatocyte plasma membrane domains by monoclonal antibodies.

Authors:  M Maurice; A M Durand-Schneider; M Garbarz; G Feldmann
Journal:  Eur J Cell Biol       Date:  1985-11       Impact factor: 4.492

2.  Identification of the hepatic asialo-glycoprotein receptor (hepatic lectin) as a component of liver specific membrane lipoprotein (LSP).

Authors:  I G McFarlane; B M McFarlane; G N Major; P Tolley; R Williams
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

3.  Efficient generation in vitro, from human peripheral blood cells, of monoclonal Epstein-Barr virus transformants producing specific antibody to a variety of antigens without prior deliberate immunization.

Authors:  L Winger; C Winger; P Shastry; A Russell; M Longenecker
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

4.  Liver cell surface expression of the antigen reacting with liver-kidney microsomal antibody (LKM).

Authors:  M Lenzi; F B Bianchi; F Cassani; E Pisi
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

5.  Identification of surface proteins on bovine leukocytes by a biotin-avidin protein blotting technique.

Authors:  W L Hurley; E Finkelstein; B D Holst
Journal:  J Immunol Methods       Date:  1985-12-17       Impact factor: 2.303

6.  Human B lymphocytes immortalization by Epstein-Barr virus in the presence of cyclosporin A.

Authors:  F Pelloquin; J P Lamelin; G M Lenoir
Journal:  In Vitro Cell Dev Biol       Date:  1986-12

7.  Detection of antibodies to herpes simplex virus with a continuous cell line expressing cloned glycoprotein D.

Authors:  P W Berman; D Dowbenko; L A Lasky; C C Simonsen
Journal:  Science       Date:  1983-11-04       Impact factor: 47.728

8.  Viral membrane proteins acquire galactose in trans Golgi cisternae during intracellular transport.

Authors:  G Griffiths; R Brands; B Burke; D Louvard; G Warren
Journal:  J Cell Biol       Date:  1982-12       Impact factor: 10.539

9.  Anti-liver-kidney microsome antibody recognizes a 50,000 molecular weight protein of the endoplasmic reticulum.

Authors:  F Alvarez; O Bernard; J C Homberg; G Kreibich
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

10.  Determination of the membrane topology of the phenobarbital-inducible rat liver cytochrome P-450 isoenzyme PB-4 using site-specific antibodies.

Authors:  C De Lemos-Chiarandini; A B Frey; D D Sabatini; G Kreibich
Journal:  J Cell Biol       Date:  1987-02       Impact factor: 10.539

View more
  8 in total

Review 1.  Xenobiotic-metabolizing enzymes as autoantigens in human autoimmune disorders. An update.

Authors:  E Boitier; P Beaune
Journal:  Clin Rev Allergy Immunol       Date:  2000-04       Impact factor: 8.667

2.  Type II autoimmune hepatitis: the conundrum of cytochrome P450IID6.

Authors:  D Vergani; G Mieli-Vergani
Journal:  Clin Exp Immunol       Date:  1993-06       Impact factor: 4.330

3.  Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.

Authors:  L Muratori; M Parola; A Ripalti; G Robino; P Muratori; G Bellomo; R Carini; M Lenzi; M P Landini; E Albano; F B Bianchi
Journal:  Gut       Date:  2000-04       Impact factor: 23.059

4.  Treatment of Autoimmune Hepatitis: Current and Future Therapies.

Authors:  Fernando Alvarez
Journal:  Curr Treat Options Gastroenterol       Date:  2004-10

5.  Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis.

Authors:  L Muratori; M Cataleta; P Muratori; M Lenzi; F B Bianchi
Journal:  Gut       Date:  1998-05       Impact factor: 23.059

Review 6.  In vitro analysis of metabolic predisposition to drug hypersensitivity reactions.

Authors:  R J Riley; J S Leeder
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

7.  Proteasome inhibition compromises direct retention of cytochrome P450 2C2 in the endoplasmic reticulum.

Authors:  Elzbieta Szczesna-Skorupa; Byron Kemper
Journal:  Exp Cell Res       Date:  2008-08-15       Impact factor: 3.905

Review 8.  Autoantibodies in Autoimmune Hepatitis: Can Epitopes Tell Us about the Etiology of the Disease?

Authors:  Urs Christen; Edith Hintermann
Journal:  Front Immunol       Date:  2018-02-16       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.